QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Non-Small Cell Lung Cancer · Small Cell Lung Cancer · Urothelial Carcinoma · Head and Neck Squamous Cell Carcinoma · Merkel Cell Carcinoma · Melanoma · Renal Cell Carcinoma · Gastric Cancer · Cervical Cancer · Hepatocellular Carcinoma · Microsatellite Instability · Mismatch Repair Deficiency · Colorectal Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 40 (planned)
- Started
- Dec 11, 2018
- Main results expected
- Aug 31, 2029
- Fully finished
- Dec 31, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.
Measured over: Evaluated from the first dose of study drug and repeated at each scheduled disease-assessment visit for up to 24 months (or until progression/death), with the time-to-response summarized using Kaplan-Meier methods
Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ
Measured over: Measured from the date of the first study-drug administration to the date of death (any cause) and followed for up to 24 months after the last dose (or until death), allowing the correlation with on-treatment ALC changes
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03228667 · record last updated 2026-01-14 · checked 2026-11-09 15:42 UTC